These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 2257485

  • 1. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.
    Hill DR, Woodruff GN.
    Brain Res; 1990 Sep 03; 526(2):276-83. PubMed ID: 2257485
    [Abstract] [Full Text] [Related]

  • 2. Autoradiographical detection of cholecystokinin-A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329.
    Hill DR, Shaw TM, Graham W, Woodruff GN.
    J Neurosci; 1990 Apr 03; 10(4):1070-81. PubMed ID: 2329368
    [Abstract] [Full Text] [Related]

  • 3. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
    Corp ES, McQuade J, Moran TH, Smith GP.
    Brain Res; 1993 Sep 24; 623(1):161-6. PubMed ID: 8221086
    [Abstract] [Full Text] [Related]

  • 4. Binding sites for 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass.
    Hill DR, Shaw TM, Woodruff GN.
    Neurosci Lett; 1988 Jun 29; 89(2):133-9. PubMed ID: 3134624
    [Abstract] [Full Text] [Related]

  • 5. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.
    Mercer JG, Lawrence CB.
    Neurosci Lett; 1992 Mar 30; 137(2):229-31. PubMed ID: 1374868
    [Abstract] [Full Text] [Related]

  • 6. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
    Graham WC, Hill DR, Woodruff GN, Sambrook MA, Crossman AR.
    Neurosci Lett; 1991 Sep 30; 131(1):129-34. PubMed ID: 1791971
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and characterization of a new labeled gastrin ligand, 125-I-BH-[Leu15]-gastrin-(5-17), on binding to canine fundic mucosal cells and Jurkat cells.
    Galleyrand JC, Lima-Leite AC, Lallement JC, Lignon MF, Bernad N, Fulcrand P, Martinez J.
    Int J Pept Protein Res; 1994 Oct 30; 44(4):348-56. PubMed ID: 7875937
    [Abstract] [Full Text] [Related]

  • 8. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
    Huang SC, Zhang L, Chiang HC, Wank SA, Maton PN, Gardner JD, Jensen RT.
    Am J Physiol; 1989 Jul 30; 257(1 Pt 1):G169-74. PubMed ID: 2473653
    [Abstract] [Full Text] [Related]

  • 9. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N, Fourmy D.
    Eur J Biochem; 1993 Mar 01; 212(2):529-38. PubMed ID: 8444190
    [Abstract] [Full Text] [Related]

  • 10. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW, Holladay MW, Barrett RW, Wolfram CA, Miller TR, Witte D, Kerwin JF, Wagenaar F, Nadzan AM.
    Mol Pharmacol; 1989 Dec 01; 36(6):881-6. PubMed ID: 2601685
    [Abstract] [Full Text] [Related]

  • 11. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W, Povoski SP, Bell RH.
    J Surg Res; 1995 Mar 01; 58(3):281-9. PubMed ID: 7533864
    [Abstract] [Full Text] [Related]

  • 12. Distribution of cholecystokinin receptors in the bovine brain: a quantitative autoradiographic study.
    Morency MA, Quirion R, Mishra RK.
    Neuroscience; 1994 Sep 01; 62(1):307-16. PubMed ID: 7816208
    [Abstract] [Full Text] [Related]

  • 13. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
    Harper EA, Griffin EP, Shankley NP, Black JW.
    Br J Pharmacol; 1999 Mar 01; 126(6):1496-503. PubMed ID: 10217545
    [Abstract] [Full Text] [Related]

  • 14. Characterization of cholecystokinin receptors on the human gallbladder.
    Tokunaga Y, Cox KL, Coleman R, Concepcion W, Nakazato P, Esquivel CO.
    Surgery; 1993 Feb 01; 113(2):155-62. PubMed ID: 7679224
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS, Lotti VJ, Chen TB, Kunkel KA.
    Mol Pharmacol; 1986 Sep 01; 30(3):212-7. PubMed ID: 3018478
    [Abstract] [Full Text] [Related]

  • 16. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Garsky VM, Gilbert KF, Leighton JL, Carson KL, Mellin EC.
    J Med Chem; 1993 Dec 24; 36(26):4276-92. PubMed ID: 8277510
    [Abstract] [Full Text] [Related]

  • 17. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Ryecroft W, Iversen LL, Iversen SD.
    Mol Pharmacol; 1994 Nov 24; 46(5):943-8. PubMed ID: 7969084
    [Abstract] [Full Text] [Related]

  • 18. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide.
    Nylander AG, Chen D, Ihse I, Rehfeld JF, Håkanson R.
    Scand J Gastroenterol; 1992 Sep 24; 27(9):743-7. PubMed ID: 1411279
    [Abstract] [Full Text] [Related]

  • 19. Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia.
    Widdop RE, Krstew E, Mercer LD, Carlberg M, Beart PM, Jarrott B.
    J Auton Nerv Syst; 1994 Sep 24; 46(1-2):65-73. PubMed ID: 8120343
    [Abstract] [Full Text] [Related]

  • 20. Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors.
    Vasar E, Harro J, Lang A, Soosaar A, Oöpik T, Kôks S, Sihver S, Volke V.
    Eur Neuropsychopharmacol; 1993 Mar 24; 3(1):63-73. PubMed ID: 8471831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.